An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer
An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer
复制标题
DOI：
10.1158/1078-0432.ccr-07-0648
复制
发表时间：
2007-11-01
影响因子：
11.5
通讯作者：
Wu, Jennifer D.
中科院分区：
文献类型：
--
作者：
Plymate, Stephen R.;Haugk, Kathy;Wu, Jennifer D.
目的：在人前列腺异种移植模型lucap35中，研究胰岛素样生长因子- ir （IGF-IR）信号的抑制与抗IGF-IR抗体A12联合雄激素停药对前列腺癌进展的影响。实验设计：将lucap35植入重度联合免疫缺陷小鼠sc。在阉割时，小鼠被随机分为三组之一。组1仅去势；2组在去势后1周开始给予A12 40 mg/kg，连续2周；3组从去势后2周开始，口服A12 40 mg/kg，连续2周。结果：1组肿瘤体积在去势后4周缩小至初始体积的60%。2、3组在去势6周后肿瘤体积减小
Purpose: To determine the effect of inhibition of insulin-like growth factor-IR (IGF-IR) signaling with an antibody to the IGF-IR, A12, in conjunction with androgen withdrawal on prostate cancer progression in a human prostate xenograft model, LuCaP 35.Experimental Design: LuCaP 35 was implanted s.c. in severe combined immunodeficient mice. At the time of castration, mice were randomized to one of three groups. Group 1 was castrate only; group 2 received A12 40 mg/kg i.p. for 2 weeks beginning 1 week after castration; and group 3 received A12 40 mg/kg i.p. for 2 weeks beginning 2 weeks after castration.Results: In group 1, tumor volume decreased to 60% of the starting volume 4 weeks post-castration. In groups 2 and 3, tumor volumes nadired 6 weeks after castration at